

Global Idiopathic Pulmonary Fibrosis Treatment Market Size study, by Drug Class (Pirfenidone, Nintedanib), Route of Administration, Distribution Channel, and Regional Forecasts 2022-2032

<https://marketpublishers.com/r/G79F83F38244EN.html>

Date: May 2025

Pages: 285

Price: US\$ 3,218.00 (Single User License)

ID: G79F83F38244EN

Abstracts

The Global Idiopathic Pulmonary Fibrosis (IPF) Treatment Market is valued at approximately USD 3.45 billion in 2023 and is anticipated to escalate with a compounded annual growth rate (CAGR) of more than 6.80% over the forecast period 2024–2032. Idiopathic Pulmonary Fibrosis, a relentlessly progressive and fatal interstitial lung disease, is reshaping the paradigms of respiratory healthcare. Characterized by chronic scarring of the lung tissue and impaired oxygen exchange, IPF has become a significant concern for both clinicians and healthcare policy-makers globally. Innovations in antifibrotic therapies such as Pirfenidone and Nintedanib have transitioned the landscape from symptom-based treatment to targeted intervention strategies, helping to delay disease progression and enhance quality of life. This shift marks a vital inflection point in the broader narrative of pulmonary care.

The market trajectory is being powered by a multifactorial confluence of demographic, technological, and regulatory elements. A steady rise in the geriatric population—who are most susceptible to IPF—coupled with increasing environmental pollutants and lifestyle risk factors such as smoking, has intensified the demand for effective long-term treatment options. The approval of IPF-specific antifibrotics has not only extended patient survival but also spurred R&D investments across pharmaceutical pipelines. Additionally, increased disease awareness campaigns and the proliferation of screening technologies are driving earlier diagnoses, which further contributes to expanding the addressable patient population. Nevertheless, the market contends with limitations including high therapy costs, limited drug efficacy for certain patient subtypes, and adverse effects that often hamper long-term treatment adherence.

Industry stakeholders are strategically leveraging emerging clinical insights and digital health tools to mitigate these challenges. Personalized medicine and biomarker-based diagnostics are being prioritized to enhance drug efficacy and optimize patient selection. Meanwhile, the growing integration of artificial intelligence in pulmonary diagnostics is streamlining treatment workflows and reducing misdiagnosis, an issue historically prevalent with IPF due to its symptomatic overlap with other lung conditions. Furthermore, supportive reimbursement frameworks in key regions are gradually lowering the financial barriers that once restricted widespread therapeutic access, accelerating market penetration.

A critical driver bolstering the IPF treatment market is the active collaboration between public institutions and biopharma giants aimed at research acceleration. Partnerships have emerged to co-develop innovative therapies and conduct expansive clinical trials with faster enrollment and turnaround. Parallely, regulatory agencies like the FDA and EMA have adopted expedited approval pathways for IPF-related treatments, ensuring faster time-to-market for promising compounds. These regulatory flexibilities are acting as a catalyst for breakthrough innovations and deepening market competition, eventually benefiting patients with more options and improved outcomes.

Geographically, North America dominates the IPF treatment landscape, driven by a well-structured healthcare ecosystem, advanced reimbursement policies, and high adoption rates of novel therapeutics. Europe closely follows, anchored by strong governmental funding in rare disease research and sophisticated clinical networks. Asia Pacific, on the other hand, is anticipated to register the fastest growth through 2032, fueled by the rapid expansion of healthcare infrastructure, heightened awareness initiatives, and a surge in clinical trial activity across countries like China, India, and Japan. Meanwhile, Latin America and the Middle East & Africa are emerging as potential growth corridors owing to the gradual rollout of diagnostic programs and growing access to essential IPF medications.

Major market player included in this report are:

Genentech, Inc.

Boehringer Ingelheim International GmbH

Hoffmann-La Roche Ltd

F. Hoffmann-La Roche AG

Bayer AG

Aspen Pharmacare

Biogen Inc.

MediciNova, Inc.

Galapagos NV

FibroGen, Inc.

United Therapeutics Corporation

AstraZeneca PLC

Veracyte, Inc.

Celgene Corporation

Pfizer Inc.

The detailed segments and sub-segment of the market are explained below:

By Drug Class

Pirfenidone

Nintedanib

By Route of Administration

Oral

Inhalation

Others

By Distribution Channel

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

By Region:

North America

U.S.

Canada

Europe

UK

Germany

France

Spain

Italy

Rest of Europe

Asia Pacific

China

India

Japan

Australia

South Korea

Rest of Asia Pacific

Latin America

Brazil

Mexico

Rest of Latin America

Middle East & Africa

Saudi Arabia

South Africa

Rest of Middle East & Africa

Years considered for the study are as follows:

Historical year – 2022

Base year – 2023

Forecast period – 2024 to 2032

Key Takeaways:

Market Estimates & Forecast for 10 years from 2022 to 2032.

Annualized revenues and regional level analysis for each market segment.

Detailed analysis of geographical landscape with country-level analysis of major regions.

Competitive landscape with information on major players in the market.

Analysis of key business strategies and recommendations on future market approach.

Analysis of competitive structure of the market.

Demand side and supply side analysis of the market.

Contents

CHAPTER 1. GLOBAL IDIOPATHIC PULMONARY FIBROSIS TREATMENT MARKET EXECUTIVE SUMMARY

- 1.1. Global IPF Treatment Market Size & Forecast (2022–2032)
- 1.2. Regional Summary
- 1.3. Segmental Summary
 - 1.3.1. By Drug Class (Pirfenidone, Nintedanib)
 - 1.3.2. By Route of Administration (Oral, Inhalation, Others)
 - 1.3.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
- 1.4. Key Trends
- 1.5. Recession Impact
- 1.6. Analyst Recommendation & Conclusion

CHAPTER 2. GLOBAL IPF TREATMENT MARKET DEFINITION AND RESEARCH ASSUMPTIONS

- 2.1. Research Objective
- 2.2. Market Definition
- 2.3. Research Assumptions
 - 2.3.1. Inclusion & Exclusion
 - 2.3.2. Limitations
 - 2.3.3. Supply Side Analysis
 - 2.3.3.1. Availability
 - 2.3.3.2. Infrastructure
 - 2.3.3.3. Regulatory Environment
 - 2.3.3.4. Market Competition
 - 2.3.3.5. Economic Viability (Patient Perspective)
 - 2.3.4. Demand Side Analysis
 - 2.3.4.1. Regulatory Frameworks
 - 2.3.4.2. Technological Advancements
 - 2.3.4.3. Environmental Considerations
 - 2.3.4.4. Patient Awareness & Acceptance
- 2.4. Estimation Methodology
- 2.5. Years Considered for the Study
- 2.6. Currency Conversion Rates

CHAPTER 3. GLOBAL IPF TREATMENT MARKET DYNAMICS

3.1. Market Drivers

- 3.1.1. Rising Geriatric Population & Environmental Risk Factors
- 3.1.2. Approval & Investment in Antifibrotic Therapies
- 3.1.3. Enhanced Screening & Early Diagnosis Initiatives

3.2. Market Challenges

- 3.2.1. High Therapy Costs & Reimbursement Barriers
- 3.2.2. Variable Drug Efficacy & Adverse Effects
- 3.2.3. Diagnostic Complexity & Misdiagnosis Risk

3.3. Market Opportunities

- 3.3.1. Personalized Medicine & Biomarker-Driven Treatment
- 3.3.2. AI-Enabled Pulmonary Diagnostics
- 3.3.3. Expansion in Emerging Markets' Healthcare Infrastructure
- 3.3.4. Next-Generation Combination Antifibrotic Therapies

CHAPTER 4. GLOBAL IPF TREATMENT MARKET INDUSTRY ANALYSIS

4.1. Porter's Five Forces Model

- 4.1.1. Bargaining Power of Suppliers
- 4.1.2. Bargaining Power of Buyers
- 4.1.3. Threat of New Entrants
- 4.1.4. Threat of Substitutes
- 4.1.5. Competitive Rivalry
- 4.1.6. Futuristic Approach to Porter's Model
- 4.1.7. Porter's Five Forces Impact Analysis

4.2. PESTEL Analysis

- 4.2.1. Political
- 4.2.2. Economic
- 4.2.3. Social
- 4.2.4. Technological
- 4.2.5. Environmental
- 4.2.6. Legal

4.3. Top Investment Opportunities

4.4. Top Winning Strategies

4.5. Disruptive Trends

4.6. Industry Expert Perspectives

4.7. Analyst Recommendation & Conclusion

CHAPTER 5. GLOBAL IPF TREATMENT MARKET SIZE & FORECASTS BY DRUG CLASS (2022–2032)

- 5.1. Segment Dashboard
- 5.2. Pirfenidone Revenue Trend Analysis, 2022 & 2032 (USD Million)
- 5.3. Nintedanib Revenue Trend Analysis, 2022 & 2032 (USD Million)

CHAPTER 6. GLOBAL IPF TREATMENT MARKET SIZE & FORECASTS BY ROUTE OF ADMINISTRATION (2022–2032)

- 6.1. Segment Dashboard
- 6.2. Oral Revenue Trend Analysis, 2022 & 2032 (USD Million)
- 6.3. Inhalation Revenue Trend Analysis, 2022 & 2032 (USD Million)
- 6.4. Others Revenue Trend Analysis, 2022 & 2032 (USD Million)

CHAPTER 7. GLOBAL IPF TREATMENT MARKET SIZE & FORECASTS BY DISTRIBUTION CHANNEL (2022–2032)

- 7.1. Segment Dashboard
- 7.2. Hospital Pharmacies Revenue Trend Analysis, 2022 & 2032 (USD Million)
- 7.3. Retail Pharmacies Revenue Trend Analysis, 2022 & 2032 (USD Million)
- 7.4. Online Pharmacies Revenue Trend Analysis, 2022 & 2032 (USD Million)

CHAPTER 8. GLOBAL IPF TREATMENT MARKET SIZE & FORECASTS BY REGION (2022–2032)

- 8.1. North America IPF Treatment Market
 - 8.1.1. U.S. IPF Market
 - 8.1.2. Canada IPF Market
- 8.2. Europe IPF Treatment Market
 - 8.2.1. UK IPF Market
 - 8.2.2. Germany IPF Market
 - 8.2.3. France IPF Market
 - 8.2.4. Spain IPF Market
 - 8.2.5. Italy IPF Market
 - 8.2.6. Rest of Europe IPF Market
- 8.3. Asia Pacific IPF Treatment Market
 - 8.3.1. China IPF Market
 - 8.3.2. India IPF Market

- 8.3.3. Japan IPF Market
- 8.3.4. Australia IPF Market
- 8.3.5. South Korea IPF Market
- 8.3.6. Rest of Asia Pacific IPF Market
- 8.4. Latin America IPF Treatment Market
 - 8.4.1. Brazil IPF Market
 - 8.4.2. Mexico IPF Market
 - 8.4.3. Rest of Latin America IPF Market
- 8.5. Middle East & Africa IPF Treatment Market
 - 8.5.1. Saudi Arabia IPF Market
 - 8.5.2. South Africa IPF Market
 - 8.5.3. Rest of Middle East & Africa IPF Market

CHAPTER 9. COMPETITIVE INTELLIGENCE

- 9.1. Key Company SWOT Analysis
 - 9.1.1. Genentech, Inc.
 - 9.1.2. Boehringer Ingelheim International GmbH
 - 9.1.3. Hoffmann-La Roche Ltd
- 9.2. Top Market Strategies
- 9.3. Company Profiles
 - 9.3.1. Genentech, Inc.
 - 9.3.1.1. Key Information
 - 9.3.1.2. Overview
 - 9.3.1.3. Financial (Subject to Data Availability)
 - 9.3.1.4. Product Summary
 - 9.3.1.5. Market Strategies
 - 9.3.2. Boehringer Ingelheim International GmbH
 - 9.3.3. Hoffmann-La Roche Ltd
 - 9.3.4. F. Hoffmann-La Roche AG
 - 9.3.5. Bayer AG
 - 9.3.6. Aspen Pharmacare
 - 9.3.7. Biogen Inc.
 - 9.3.8. MediciNova, Inc.
 - 9.3.9. Galapagos NV
 - 9.3.10. FibroGen, Inc.
 - 9.3.11. United Therapeutics Corporation
 - 9.3.12. AstraZeneca PLC
 - 9.3.13. Veracyte, Inc.

9.3.14. Celgene Corporation

9.3.15. Pfizer Inc.

CHAPTER 10. RESEARCH PROCESS

10.1. Research Process Overview

10.1.1. Data Mining

10.1.2. Analysis

10.1.3. Market Estimation

10.1.4. Validation

10.1.5. Publishing

10.2. Research Attributes

I would like to order

Product name: Global Idiopathic Pulmonary Fibrosis Treatment Market Size study, by Drug Class (Pirfenidone, Nintedanib), Route of Administration, Distribution Channel, and Regional Forecasts 2022-2032

Product link: <https://marketpublishers.com/r/G79F83F38244EN.html>

Price: US\$ 3,218.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G79F83F38244EN.html>